Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HUTCHMED (China) ( (HK:0013) ) has issued an update.
HUTCHMED announced that it will present new preclinical and clinical data at the American Association for Cancer Research Annual Meeting 2026, highlighting advances from its in-house oncology pipeline. The data include preclinical results for HMPL-A580, a first-in-class antibody-targeted therapy conjugate that links a novel, highly selective PI3K/PІKK inhibitor payload to an anti-EGFR antibody, showing potent, EGFR-directed anti-tumor activity, strong bystander effects, and favorable pharmacokinetics in multiple preclinical models.
The company will also showcase updated Phase Ib/II data on a triple-combination regimen of surufatinib, sintilimab and capecitabine in previously treated metastatic small bowel and appendiceal cancers, along with an exploratory Phase II study of surufatinib plus gemcitabine and nab-paclitaxel in pancreatic ductal adenocarcinoma after induction therapy. These disclosures underscore HUTCHMED’s push to build a differentiated next-generation ATTC platform targeting the PAM pathway, enhance the clinical positioning of surufatinib in difficult-to-treat solid tumors, and prepare its ATTC technology for global partnering, potentially strengthening its oncology franchise and international footprint.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$23.50 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. The company, which markets three medicines in China and has one product also approved in the US, Europe and Japan, retains global rights to its oral angio-immuno kinase inhibitor surufatinib, sold domestically as SULANDA, and leverages partnerships with multinational drugmakers to expand its portfolio worldwide.
Average Trading Volume: 4,676,505
Technical Sentiment Signal: Sell
Current Market Cap: HK$20.55B
See more insights into 0013 stock on TipRanks’ Stock Analysis page.